The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Overcoming barriers to referral for CAR-T cell therapy in R/R DLBCL
Marc Hoffmann, MD, The University of Kansas, Kansas City, KS, highlights the key barriers to referral, which have extended from transplantation to CAR T-cell therapy in diffuse large B-cell lymphoma (DLBCL) and have led to only around one-third of patients eligible for CAR-T receiving the treatment. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Pharmacyclics LLC (an AbbVie Company)
Honoraria: Pharmacyclics LLC (an AbbVie Company)
